31 May 2010 in Journal of Experimental Medicine
How proliferative and inhibitory signals integrate to control liver regeneration remains poorly understood. A screen for antiproliferative factors repressed after liver injury identified transducer of ErbB2.1 (Tob1), a member of the PC3/BTG1 family of mito-inhibitory molecules as a target for further evaluation. Tob1 protein decreases after 2/3 hepatectomy in mice secondary to posttranscriptional mechanisms. Deletion of Tob1 increases hepatocyte proliferation and accelerates restoration of liver mass after hepatectomy. Down-regulation of Tob1 is required for normal liver regeneration, and Tob1 controls hepatocyte proliferation in a dose-dependent fashion. Tob1 associates directly with both Caf1 and cyclin-dependent kinase (Cdk) 1 and modulates Cdk1 kinase activity. In addition, Tob1 has significant effects on the transcription of critical cell cycle components, including E2F target genes and genes involved in p53 signaling. We provide direct evidence that levels of an inhibitory factor control the rate of liver regeneration, and we identify Tob1 as a crucial check point molecule that modulates the expression and activity of cell cycle proteins.
29 November 2022 in Surgery
6 October 2022 in Transplantation Proceedings
1 May 2022 in Revista médica de Chile
<![CDATA[In Chile, colorectal cancer ranks third in incidence and fifth in mortality. Half of these patients have liver metastases at the diagnosis, and only 30% of them are resectable. Despite the development of many complex hepatobiliary procedures to achieve the total resection of metastases, the long-term survival with these techniques is not good. Liver transplantation is an alternative to treat unresectable liver metastasis from colorectal cancer with a good outcome. Several prognostic scores allow the selection of patients with good tumor biology. These patients have better overall and disease-free survival after liver transplantation. The use of immunosuppressive treatment doesn't increase recurrence, and even the pattern of tumor growth is slower in liver transplant recipients. The purpose of this review is to summarize the current evidence in this topic and to highlight the need for a formal protocol for liver transplantation for unresectable colorectal liver metastases, using living donors or marginal grafts to avoid competition with the rest of the national waiting list.]]>
2 September 2025 in The American Journal of Surgery
1 January 2025 in Translational Gastroenterology and Hepatology
Background: Living donor selection is crucial to minimize postoperative donor complications and to improve recipient outcomes. This study describes the selection process and evaluates the reasons for discarding potential donors in our living donor liver transplantation (LDLT) program. Methods: Retrospective descriptive analysis from all potential donors evaluated in our LDLT program between April 2018 and July 2021. Selection criteria included age 18–60 years old, no significant medical or mental comorbidities, ABO and anatomical suitability. Results: A total of 231 potential donors were evaluated. Mean age was 37.2±11.1 years and male gender in 51.9%. One hundred and one potential donors (43.7%) did not complete the evaluation, mainly because of availability of a deceased donor during the process (n=32; 13.9%), ABO incompatibility (n=14; 6.1%), progression or death of the recipient (n=20; 8.7%). Of the 130 who completed their radiological evaluation, 55 (42.3%) were anatomically unsuitable, mainly due to small liver remnant size (n=25/130; 19.2%) and steatosis (n=17/130; 13.1%). Out of the 231 potential donors, 75 were accepted as adequate donors (32.5%) and 36 candidates underwent liver donation (15.6%). Conclusions: Only one-third of all potential donors are suitable for donation and half of them will undergo surgery. Given that in our setting computed tomography (CT) has a lower cost than magnetic resonance imaging (MRI), starting with a CT scan decreases the high cost of further workup of donors that are not anatomically suitable for living liver donation.